Alder Biopharmaceuticals Stock Price, News & Analysis (NASDAQ:ALDR)

$13.85 +0.30 (+2.21 %)
(As of 02/21/2018 02:19 AM ET)
Previous Close$13.85
Today's Range$13.45 - $14.18
52-Week Range$8.60 - $24.65
Volume1.47 million shs
Average Volume2.13 million shs
Market Capitalization$937.83 million
P/E Ratio-2.58
Dividend YieldN/A
Beta2.6

About Alder Biopharmaceuticals (NASDAQ:ALDR)

Alder Biopharmaceuticals logoAlder BioPharmaceuticals, Inc., is a clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize genetically engineered therapeutic antibodies with the potential to meaningfully transform current treatment paradigms. Alder's lead pivotal-stage product candidate, eptinezumab, is being evaluated for migraine prevention. Eptinezumab is a monoclonal antibody that inhibits calcitonin gene-related peptide (CGRP), a protein that is active in mediating the initiation of migraine. Alder is additionally evaluating ALD1910, a preclinical product candidate also in development as a migraine prevention therapy. ALD1910 is a monoclonal antibody that inhibits pituitary adenylate cyclase-activating polypeptide-38 (PACAP-38), another protein that is active in mediating the initiation of migraine. Clazakizumab, Alder's third program, is a monoclonal antibody candidate that inhibits interleukin-6 and is licensed to Vitaeris, Inc.

Receive ALDR News and Ratings via Email

Sign-up to receive the latest news and ratings for ALDR and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorHealthcare
SymbolNASDAQ:ALDR
CUSIPN/A
Phone+1-425-2052900

Debt

Debt-to-Equity RatioN/A
Current Ratio9.03%
Quick Ratio9.01%

Price-To-Earnings

Trailing P/E Ratio-2.57914338919925
Forward P/E Ratio-2.69
P/E GrowthN/A

Sales & Book Value

Annual Sales$110,000.00
Price / Sales8,541.67
Cash FlowN/A
Price / CashN/A
Book Value$7.61 per share
Price / Book1.82

Profitability

Trailing EPS($5.37)
Net Income$-156,250,000.00
Net MarginsN/A
Return on Equity-93.14%
Return on Assets-84.14%

Miscellaneous

Employees176
Outstanding Shares67,840,000

Alder Biopharmaceuticals (NASDAQ:ALDR) Frequently Asked Questions

What is Alder Biopharmaceuticals' stock symbol?

Alder Biopharmaceuticals trades on the NASDAQ under the ticker symbol "ALDR."

How were Alder Biopharmaceuticals' earnings last quarter?

Alder Biopharmaceuticals Inc (NASDAQ:ALDR) released its earnings results on Tuesday, November, 7th. The biopharmaceutical company reported ($0.92) EPS for the quarter, topping analysts' consensus estimates of ($1.21) by $0.29. During the same quarter last year, the firm earned ($0.70) earnings per share. View Alder Biopharmaceuticals' Earnings History.

Where is Alder Biopharmaceuticals' stock going? Where will Alder Biopharmaceuticals' stock price be in 2018?

12 equities research analysts have issued 12 month price objectives for Alder Biopharmaceuticals' shares. Their forecasts range from $11.00 to $51.00. On average, they expect Alder Biopharmaceuticals' stock price to reach $30.42 in the next year. View Analyst Ratings for Alder Biopharmaceuticals.

What are Wall Street analysts saying about Alder Biopharmaceuticals stock?

Here are some recent quotes from research analysts about Alder Biopharmaceuticals stock:

  • 1. According to Zacks Investment Research, "Alder Biopharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It discovers, develops and seeks to commercialize therapeutic antibodies. It is developing monoclonal antibodies comprising ALD403, for the prevention of migraine; and Clazakizumab, in the treatment of rheumatoid arthritis and psoriatic arthritis. Alder Biopharmaceuticals Inc. is headquartered in Bothell, Washington. " (1/11/2018)
  • 2. Mizuho analysts commented, "We received an email from Alder yesterday on its recap of the 18th Congress of the International Headache Society (IHC) meeting as it relates to eptinezumab. What we found as incremental data points are Alder’s interviews with practicing physicians on the advantages of eptinezumab. We believe the IV formulation for eptinezumab is a positive differentiation from other CGRP products in late stage development because of its reimbursement and potentially better compliance." (9/15/2017)
  • 3. Needham & Company LLC analysts commented, "Results from the ongoing pivotal Phase 3 PROMISE-1 trial in patients with frequent episodic migraines (FEM) are expected this month. In the context of positive Phase 3 FEM results from all competitor CGRP antibody programs (AMGN, LLY, TEVA), we think PROMISE-1’s primary endpoint will generally be in-line with the competition. However, we expect differentiation with key secondary endpoints (≥75% reduction in migraine days over weeks 1-12 and weeks 1-4), which we think will be important for commercial success. We maintain our view that there is room for multiple players in the migraine prophylaxis market, and we believe Alder shares remain underappreciated even in a scenario where PROMISE-1 data are positive but undifferentiated. Alder’s current EV (~$550M) reflects treatment of just ~63k patients with eptinezumab in 2027 in our model, or <1% of our estimated 7.1M prevention therapy candidates."" (6/9/2017)
  • 4. Aegis analysts commented, "We conducted an in-depth analysis of four late-stage monoclonal antibodies in development for migraine prevention – See table 1." (4/10/2017)

Who are some of Alder Biopharmaceuticals' key competitors?

Who are Alder Biopharmaceuticals' key executives?

Alder Biopharmaceuticals' management team includes the folowing people:

  • Stephen M. Dow, Independent Chairman of the Board (Age 61)
  • Randall C. Schatzman Ph.D., President, Chief Executive Officer, Director (Age 62)
  • Larry K. Benedict, Executive Vice President, Principal Accounting Officer (Age 56)
  • Elisabeth A. Sandoval, Chief Commercial Officer and Executive Vice President of Corporate Strategy (Age 55)
  • James B. Bucher J.D., Senior Vice President, General Counsel (Age 51)
  • Randal A. Hassler, Senior Vice President - Pharmaceutical Operations (Age 59)
  • John A. Latham Ph.D., Chief Scientific Officer (Age 57)
  • Mark James Litton Ph.D., Chief Business Officer, Treasurer and Secretary (Age 49)
  • Jeffrey T.L. Smith M.D., Managing Director of Alder BioPharmaceuticals Limited (Age 57)
  • Paul Rutherford Carter, Independent Director (Age 56)

Who owns Alder Biopharmaceuticals stock?

Alder Biopharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Redmile Group LLC (9.59%), BlackRock Inc. (7.34%), Palo Alto Investors LLC (2.71%), Emerald Advisers Inc. PA (2.55%), Goldman Sachs Group Inc. (2.45%) and Pinnacle Associates Ltd. (1.99%). Company insiders that own Alder Biopharmaceuticals stock include Jeffrey T L Smith, John A Latham, Mark James Litton, Randall C Schatzman and Stephen M Dow. View Institutional Ownership Trends for Alder Biopharmaceuticals.

Who sold Alder Biopharmaceuticals stock? Who is selling Alder Biopharmaceuticals stock?

Alder Biopharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Wells Fargo & Company MN, BlackRock Inc., Metropolitan Life Insurance Co. NY, Candriam Luxembourg S.C.A., Baird Financial Group Inc., Rhumbline Advisers and Sequoia Financial Advisors LLC. Company insiders that have sold Alder Biopharmaceuticals company stock in the last year include Jeffrey T L Smith and Mark James Litton. View Insider Buying and Selling for Alder Biopharmaceuticals.

Who bought Alder Biopharmaceuticals stock? Who is buying Alder Biopharmaceuticals stock?

Alder Biopharmaceuticals' stock was bought by a variety of institutional investors in the last quarter, including Palo Alto Investors LLC, Carillon Tower Advisers Inc., Brown Advisory Inc., TIAA CREF Investment Management LLC, Millennium Management LLC, Rock Springs Capital Management LP, Ascend Capital LLC and Emerald Advisers Inc. PA. View Insider Buying and Selling for Alder Biopharmaceuticals.

How do I buy Alder Biopharmaceuticals stock?

Shares of Alder Biopharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Alder Biopharmaceuticals' stock price today?

One share of Alder Biopharmaceuticals stock can currently be purchased for approximately $13.85.

How big of a company is Alder Biopharmaceuticals?

Alder Biopharmaceuticals has a market capitalization of $937.83 million and generates $110,000.00 in revenue each year. The biopharmaceutical company earns $-156,250,000.00 in net income (profit) each year or ($5.37) on an earnings per share basis. Alder Biopharmaceuticals employs 176 workers across the globe.

How can I contact Alder Biopharmaceuticals?

Alder Biopharmaceuticals' mailing address is 11804 N Creek Pkwy S, BOTHELL, WA 98011-8801, United States. The biopharmaceutical company can be reached via phone at +1-425-2052900 or via email at [email protected]


MarketBeat Community Rating for Alder Biopharmaceuticals (ALDR)

Community Ranking:  3.3 out of 5 (star star star)
Outperform Votes:  257 (Vote Outperform)
Underperform Votes:  137 (Vote Underperform)
Total Votes:  394
MarketBeat's community ratings are surveys of what our community members think about Alder Biopharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Alder Biopharmaceuticals (NASDAQ:ALDR) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.922.922.922.90
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $30.42$30.42$30.58$36.30
Price Target Upside: 114.20% upside69.93% upside152.23% upside282.11% upside

Alder Biopharmaceuticals (NASDAQ:ALDR) Consensus Price Target History

Price Target History for Alder Biopharmaceuticals (NASDAQ:ALDR)

Alder Biopharmaceuticals (NASDAQ:ALDR) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/31/2018MizuhoReiterated RatingBuy$29.00LowView Rating Details
1/12/2018Canaccord GenuitySet Price TargetBuy -> Buy$20.00 -> $22.00LowView Rating Details
1/9/2018BMO Capital MarketsBoost Price TargetOutperform$26.00HighView Rating Details
9/26/2017CowenInitiated CoverageOutperform$20.00LowView Rating Details
9/14/2017Royal Bank of CanadaInitiated CoverageOutperform -> Outperform$17.00HighView Rating Details
8/24/2017Credit Suisse GroupSet Price TargetHold$17.00 -> $11.00HighView Rating Details
8/10/2017Needham & Company LLCReiterated RatingBuy$36.00 -> $26.00HighView Rating Details
7/5/2017AegisReiterated RatingBuy$41.00LowView Rating Details
6/28/2017Wells Fargo & CoReiterated RatingOutperform$51.00HighView Rating Details
6/28/2017Piper Jaffray CompaniesReiterated RatingOverweight$47.00HighView Rating Details
6/12/2017Leerink SwannReiterated RatingOutperform$32.00MediumView Rating Details
4/17/2017Jefferies GroupReiterated RatingBuy$43.00LowView Rating Details
9/30/2016Brean CapitalInitiated CoverageBuy$45.00N/AView Rating Details
9/13/2016JPMorgan Chase & Co.Initiated CoverageOverweight$40.00N/AView Rating Details
(Data available from 2/21/2016 forward)

Earnings

Alder Biopharmaceuticals (NASDAQ:ALDR) Earnings History and Estimates Chart

Earnings by Quarter for Alder Biopharmaceuticals (NASDAQ:ALDR)

Alder Biopharmaceuticals (NASDAQ ALDR) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/7/2017Q3 2017($1.21)($0.92)ViewN/AView Earnings Details
8/8/2017Q2 2017($1.67)($1.48)$0.68 millionViewListenView Earnings Details
4/27/2017Q1 2017($0.95)($1.99)ViewN/AView Earnings Details
2/23/2017Q4 2016($0.90)($0.97)ViewN/AView Earnings Details
10/27/2016Q3($0.85)($0.70)ViewListenView Earnings Details
7/26/2016Q2($0.75)($0.79)$1.14 million$0.11 millionViewListenView Earnings Details
4/28/2016Q1($0.72)($0.76)$0.14 millionViewN/AView Earnings Details
2/23/2016Q4($0.65)($0.60)ViewListenView Earnings Details
11/5/2015Q315($0.51)($0.62)$0.23 millionViewN/AView Earnings Details
8/5/2015Q215($0.40)($0.46)$0.23 millionViewN/AView Earnings Details
5/7/2015Q115($0.37)($0.40)ViewListenView Earnings Details
3/4/2015Q414($0.18)($0.22)$5.70 million$6.40 millionViewN/AView Earnings Details
11/3/2014Q314$0.05$0.88$14.84 million$38.75 millionViewN/AView Earnings Details
8/5/2014Q2($0.22)($0.40)$5.00 million$4.70 millionViewN/AView Earnings Details
6/20/2014Q1($0.22)($5.38)$4.60 million$4.80 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Alder Biopharmaceuticals (NASDAQ:ALDR) Earnings Estimates

2018 EPS Consensus Estimate: ($4.16)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($1.38)($1.38)($1.38)
Q2 20181($1.03)($1.03)($1.03)
Q3 20181($0.91)($0.91)($0.91)
Q4 20181($0.84)($0.84)($0.84)
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for Alder Biopharmaceuticals (NASDAQ:ALDR)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Alder Biopharmaceuticals (NASDAQ ALDR) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 10.60%
Institutional Ownership Percentage: 95.34%
Insider Trades by Quarter for Alder Biopharmaceuticals (NASDAQ:ALDR)
Institutional Ownership by Quarter for Alder Biopharmaceuticals (NASDAQ:ALDR)

Alder Biopharmaceuticals (NASDAQ ALDR) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/13/2017Mark James LittonInsiderSell16,519$10.80$178,405.20116,451View SEC Filing  
10/16/2017Mark James LittonInsiderSell16,520$12.33$203,691.60116,452View SEC Filing  
7/18/2017Stephen M DowDirectorBuy25,000$10.00$250,000.00View SEC Filing  
6/20/2017Jeffrey T L SmithVPSell585$20.00$11,700.001,416View SEC Filing  
1/18/2017Mark James LittonInsiderSell1,498$23.10$34,603.80101,430View SEC Filing  
1/9/2017Mark James LittonInsiderSell9,516$23.01$218,963.16View SEC Filing  
12/1/2016Jeffrey T. L. SmithVPSell3,000$22.78$68,340.00View SEC Filing  
12/1/2016John A. LathamInsiderSell3,636$22.78$82,828.08View SEC Filing  
11/7/2016Randall C SchatzmanCEOSell10,000$25.16$251,600.00124,768View SEC Filing  
10/17/2016Mark James LittonInsiderSell6,000$27.50$165,000.0099,567View SEC Filing  
10/3/2016Jeffrey T L SmithVPSell3,000$31.14$93,420.003,000View SEC Filing  
10/3/2016John A LathamInsiderSell10,000$31.32$313,200.00252,200View SEC Filing  
10/3/2016Randall C SchatzmanCEOSell8,181$31.15$254,838.15122,949View SEC Filing  
9/1/2016Jeffrey T L SmithVPSell3,000$32.49$97,470.003,000View SEC Filing  
9/1/2016Randall C SchatzmanInsiderSell10,000$32.48$324,800.00124,768View SEC Filing  
8/15/2016Jeffrey T L SmithVPSell3,000$31.17$93,510.003,000View SEC Filing  
8/1/2016John A LathamInsiderSell10,000$31.19$311,900.00252,200View SEC Filing  
7/27/2016John A LathamInsiderSell10,000$30.14$301,400.00243,013View SEC Filing  
7/25/2016Randall C SchatzmanInsiderSell10,000$28.08$280,800.00124,768View SEC Filing  
6/13/2016Mark James LittonInsiderSell6,000$28.94$173,640.0074,567View SEC Filing  
6/3/2016Jeffrey T L SmithVPSell16,090$30.20$485,918.0016,090View SEC Filing  
6/1/2016John A LathamInsiderSell10,000$30.02$300,200.00252,200View SEC Filing  
5/31/2016Mark James LittonInsiderSell25,000$30.05$751,250.0079,847View SEC Filing  
5/27/2016John A LathamInsiderSell6,401$30.05$192,350.05248,601View SEC Filing  
5/24/2016Randall C SchatzmanCEOSell10,000$28.02$280,200.00115,933View SEC Filing  
4/18/2016Randall C SchatzmanCEOSell30,000$28.07$842,100.00124,409View SEC Filing  
1/4/2016Mark James LittoninsiderSell25,000$31.40$785,000.0073,718View SEC Filing  
1/4/2016Randall C. SchatzmanCEOSell10,000$31.47$314,700.00111,579View SEC Filing  
12/1/2015Jeffrey T. L. SmithVPSell4,272$37.24$159,089.28View SEC Filing  
12/1/2015John A. LathaminsiderSell4,550$37.24$169,442.00241,726View SEC Filing  
12/1/2015Randall C. SchatzmanCEOSell10,000$37.24$372,400.00111,579View SEC Filing  
11/30/2015Stephen M DowDirectorSell88$37.11$3,265.68View SEC Filing  
11/2/2015Jeffrey T. L. SmithVPSell3,900$33.67$131,313.00View SEC Filing  
11/2/2015John A. LathaminsiderSell4,545$33.69$153,121.05241,265View SEC Filing  
11/2/2015Randall C. SchatzmanCEOSell10,000$33.71$337,100.00109,921View SEC Filing  
10/1/2015Jeffrey T. L. SmithVPSell3,900$32.25$125,775.00View SEC Filing  
10/1/2015John A. LathaminsiderSell4,545$32.26$146,621.70241,265View SEC Filing  
9/1/2015Jeffrey T. L. SmithVPSell3,900$38.50$150,150.00View SEC Filing  
9/1/2015John A. LathaminsiderSell4,545$38.52$175,073.40209,447View SEC Filing  
8/31/2015Stephen M DowDirectorSell16,218$38.75$628,447.50View SEC Filing  
6/12/2015Larry BenedictVPSell25,454$47.46$1,208,046.84View SEC Filing  
6/4/2015John A LathamInsiderSell25,000$44.18$1,104,500.00View SEC Filing  
6/1/2015Jeffrey T L SmithVPSell3,900$41.53$161,967.00View SEC Filing  
6/1/2015John A LathamInsiderSell4,545$41.53$188,753.85View SEC Filing  
5/22/2015Jeffrey T L SmithVPSell61,818$38.86$2,402,247.48View SEC Filing  
5/21/2015Stephen M DowDirectorSell20,000$65.69$1,313,800.00View SEC Filing  
5/20/2015Stephen M DowDirectorSell8,462$40.39$341,780.18View SEC Filing  
5/18/2015Clay B SiegallDirectorSell38,181$37.62$1,436,369.22View SEC Filing  
4/1/2015Jeffrey T L SmithVPSell3,900$27.43$106,977.00View SEC Filing  
4/1/2015John A LathamInsiderSell19,045$29.54$562,589.30View SEC Filing  
3/30/2015John A LathamInsiderSell14,500$30.20$437,900.00View SEC Filing  
1/27/2015Jeffrey T L SmithVPSell3,900$28.01$109,239.00View SEC Filing  
1/27/2015John A LathamInsiderSell15,045$28.33$426,224.85View SEC Filing  
1/27/2015Randall C SchatzmanCEOSell100,000$28.42$2,842,000.00View SEC Filing  
1/26/2015Jeffrey T L SmithVPSell2,700$27.89$75,303.00View SEC Filing  
1/26/2015Mark James LittonInsiderSell5,200$28.03$145,756.00View SEC Filing  
1/26/2015Randall C SchatzmanCEOSell36,422$27.93$1,017,266.46View SEC Filing  
11/24/2014Jeffrey T L SmithVPSell29,090$16.08$467,767.20View SEC Filing  
5/13/2014A/S NovoInsiderBuy550,000$10.00$5,500,000.00View SEC Filing  
5/13/2014Alan Bruce MontgomeryDirectorBuy3,000$10.00$30,000.00View SEC Filing  
5/13/2014West 8 Limited Partne VenturesMajor ShareholderBuy250,000$10.00$2,500,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Alder Biopharmaceuticals (NASDAQ ALDR) News Headlines

Source:
DateHeadline
Alder BioPharmaceuticals® to Host Conference Call to Discuss Fourth Quarter and Year-End 2017 Financial and Operating ResultsAlder BioPharmaceuticals® to Host Conference Call to Discuss Fourth Quarter and Year-End 2017 Financial and Operating Results
finance.yahoo.com - February 19 at 5:09 PM
Alder BioPharmaceuticals® to Host Conference Call to Discuss Fourth Quarter and Year-End 2017 Financial and ... - GlobeNewswire (press release)Alder BioPharmaceuticals® to Host Conference Call to Discuss Fourth Quarter and Year-End 2017 Financial and ... - GlobeNewswire (press release)
globenewswire.com - February 19 at 8:18 AM
Stock Traders Buy High Volume of Put Options on Alder Biopharmaceuticals (ALDR)Stock Traders Buy High Volume of Put Options on Alder Biopharmaceuticals (ALDR)
www.americanbankingnews.com - February 14 at 7:38 PM
Alder BioPharmaceuticals® to Present at Two Upcoming February Investor ConferencesAlder BioPharmaceuticals® to Present at Two Upcoming February Investor Conferences
finance.yahoo.com - February 8 at 8:12 AM
 Brokerages Expect Alder Biopharmaceuticals Inc (ALDR) to Announce -$1.08 EPS Brokerages Expect Alder Biopharmaceuticals Inc (ALDR) to Announce -$1.08 EPS
www.americanbankingnews.com - February 7 at 1:10 AM
Alder Biopharmaceuticals Makes A Comeback - Seeking AlphaAlder Biopharmaceuticals Makes A Comeback - Seeking Alpha
seekingalpha.com - February 4 at 3:52 PM
Alder BioPharmaceuticals, Inc. Announces Closing of $250 Million of 2.50% Convertible Senior Notes Due 2025Alder BioPharmaceuticals, Inc. Announces Closing of $250 Million of 2.50% Convertible Senior Notes Due 2025
finance.yahoo.com - February 1 at 3:43 PM
Alder BioPharmaceuticals (ALDR) Rating Reiterated by MizuhoAlder BioPharmaceuticals (ALDR) Rating Reiterated by Mizuho
www.americanbankingnews.com - January 31 at 5:34 PM
Alder BioPharmaceuticals, Inc. (ALDR) Given Average Rating of "Buy" by AnalystsAlder BioPharmaceuticals, Inc. (ALDR) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - January 30 at 3:34 PM
Heres Why Alder Biopharmaceuticals Inc. Is Falling TodayHere's Why Alder Biopharmaceuticals Inc. Is Falling Today
finance.yahoo.com - January 30 at 9:31 AM
Alder BioPharmaceuticals, Inc.  Announces Offering of $200 Million of Convertible Senior Notes Due 2025Alder BioPharmaceuticals, Inc.  Announces Offering of $200 Million of Convertible Senior Notes Due 2025
finance.yahoo.com - January 29 at 9:49 AM
Alder BioPharmaceuticals (ALDR) versus Celsion (CLSN) Financial SurveyAlder BioPharmaceuticals (ALDR) versus Celsion (CLSN) Financial Survey
www.americanbankingnews.com - January 21 at 11:10 PM
Alder BioPharmaceuticals, Inc. (ALDR) Expected to Post Earnings of -$1.08 Per ShareAlder BioPharmaceuticals, Inc. (ALDR) Expected to Post Earnings of -$1.08 Per Share
www.americanbankingnews.com - January 21 at 5:24 AM
Cramer reveals the biggest winners and losers from the JP Morgan Healthcare ConferenceCramer reveals the biggest winners and losers from the JP Morgan Healthcare Conference
finance.yahoo.com - January 17 at 11:29 AM
Today’s Research Reports on Trending Tickers: Keryx Biopharmaceuticals and Alder BioPharmaceuticalsToday’s Research Reports on Trending Tickers: Keryx Biopharmaceuticals and Alder BioPharmaceuticals
finance.yahoo.com - January 15 at 9:40 AM
Meet the Top Biotech Movers of This Past WeekMeet the Top Biotech Movers of This Past Week
247wallst.com - January 13 at 9:58 AM
Cramer Remix: Tuesdays the day to buy FacebookCramer Remix: Tuesday's the day to buy Facebook
finance.yahoo.com - January 13 at 9:58 AM
Breakthrough treatment for migraines on path to FDA appro...Breakthrough treatment for migraines on path to FDA appro...
finance.yahoo.com - January 13 at 9:58 AM
Canaccord Genuity Analysts Give Alder BioPharmaceuticals (ALDR) a $22.00 Price TargetCanaccord Genuity Analysts Give Alder BioPharmaceuticals (ALDR) a $22.00 Price Target
www.americanbankingnews.com - January 12 at 1:26 PM
Alder BioPharmaceuticals (ALDR) Downgraded by Zacks Investment ResearchAlder BioPharmaceuticals (ALDR) Downgraded by Zacks Investment Research
www.americanbankingnews.com - January 11 at 4:52 PM
Alder Biopharmaceuticals Meets 80-Plus Relative Strength Rating BenchmarkAlder Biopharmaceuticals Meets 80-Plus Relative Strength Rating Benchmark
finance.yahoo.com - January 11 at 3:30 PM
Leerink Swann Weighs in on Alder BioPharmaceuticals, Inc.s Q1 2018 Earnings (ALDR)Leerink Swann Weighs in on Alder BioPharmaceuticals, Inc.'s Q1 2018 Earnings (ALDR)
www.americanbankingnews.com - January 11 at 10:00 AM
Alder BioPharmaceuticals (ALDR) Jumps: Stock Rises 15.5%Alder BioPharmaceuticals (ALDR) Jumps: Stock Rises 15.5%
finance.yahoo.com - January 10 at 10:28 AM
Teva Announces Licence Agreement With Alder For Anti-CGRP Antibodies PatentTeva Announces Licence Agreement With Alder For Anti-CGRP Antibodies Patent
www.nasdaq.com - January 8 at 11:03 AM
Alder Announces Eptinezumab Significantly Reduces Migraine Risk Meets Primary and All Key Secondary Endpoints in Pivotal PROMISE 2 Phase 3 Trial for Chronic Migraine PreventionAlder Announces Eptinezumab Significantly Reduces Migraine Risk Meets Primary and All Key Secondary Endpoints in Pivotal PROMISE 2 Phase 3 Trial for Chronic Migraine Prevention
finance.yahoo.com - January 8 at 11:03 AM
Alder Announces $250 Million Committed Equity FinancingAlder Announces $250 Million Committed Equity Financing
finance.yahoo.com - January 8 at 11:03 AM
Alder BioPharmaceuticals® Enters into European Patent Settlement and Global License Agreement with Teva in the Field of Anti-CGRP-Based TherapyAlder BioPharmaceuticals® Enters into European Patent Settlement and Global License Agreement with Teva in the Field of Anti-CGRP-Based Therapy
finance.yahoo.com - January 8 at 11:03 AM
Why Alder Biopharma Is Winning Big on MondayWhy Alder Biopharma Is Winning Big on Monday
finance.yahoo.com - January 8 at 11:03 AM
DELTA DRONE :Half-yearly report on the liquidity agreement with Louis Capital MarketsDELTA DRONE :Half-yearly report on the liquidity agreement with Louis Capital Markets
finance.yahoo.com - January 5 at 3:30 PM
Alder BioPharmaceuticals, Inc. (ALDR) Receives Consensus Rating of "Buy" from AnalystsAlder BioPharmaceuticals, Inc. (ALDR) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - January 5 at 3:28 PM
Alder BioPharmaceuticals (ALDR) Lifted to Sell at ValuEngineAlder BioPharmaceuticals (ALDR) Lifted to Sell at ValuEngine
www.americanbankingnews.com - January 4 at 11:12 PM
What Do Analysts Think About Alder Biopharmaceuticals Inc’s (NASDAQ:ALDR) Earnings Trend?What Do Analysts Think About Alder Biopharmaceuticals Inc’s (NASDAQ:ALDR) Earnings Trend?
finance.yahoo.com - January 4 at 9:58 AM
DELTA DRONE : strengthens its position in Africa and now wholly owns Delta Drone AfricaDELTA DRONE : strengthens its position in Africa and now wholly owns Delta Drone Africa
finance.yahoo.com - January 3 at 3:28 PM
Alder BioPharmaceuticals® to Present at the 36th Annual J.P. Morgan Healthcare ConferenceAlder BioPharmaceuticals® to Present at the 36th Annual J.P. Morgan Healthcare Conference
finance.yahoo.com - January 3 at 11:01 AM
Pre-Market Technical Scan on Biotech Equities -- Aurinia Pharma, Alder Biopharma, Achaogen, and Immunomedics - PR Newswire (press release)Pre-Market Technical Scan on Biotech Equities -- Aurinia Pharma, Alder Biopharma, Achaogen, and Immunomedics - PR Newswire (press release)
www.prnewswire.com - January 2 at 3:38 PM
Alder BioPharmaceuticals (ALDR) Raised to "Sell" at BidaskClubAlder BioPharmaceuticals (ALDR) Raised to "Sell" at BidaskClub
www.americanbankingnews.com - December 29 at 12:36 PM
Alder BioPharmaceuticals (ALDR) Lowered to "Strong Sell" at BidaskClubAlder BioPharmaceuticals (ALDR) Lowered to "Strong Sell" at BidaskClub
www.americanbankingnews.com - December 24 at 12:28 PM
Alder Biopharmaceuticals, Inc. – Value Analysis (NASDAQ:ALDR) : December 18, 2017Alder Biopharmaceuticals, Inc. – Value Analysis (NASDAQ:ALDR) : December 18, 2017
finance.yahoo.com - December 19 at 9:52 AM
Alder Biopharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : ALDR-US : December 15, 2017Alder Biopharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : ALDR-US : December 15, 2017
finance.yahoo.com - December 15 at 9:43 AM
Alder BioPharmaceuticals (ALDR) & Its Competitors Critical ReviewAlder BioPharmaceuticals (ALDR) & Its Competitors Critical Review
www.americanbankingnews.com - December 15 at 9:14 AM
Alder BioPharmaceuticals (ALDR) and The Competition Critical SurveyAlder BioPharmaceuticals (ALDR) and The Competition Critical Survey
www.americanbankingnews.com - December 3 at 7:30 PM
Alder BioPharmaceuticals (ALDR) vs. Its Competitors Financial ContrastAlder BioPharmaceuticals (ALDR) vs. Its Competitors Financial Contrast
www.americanbankingnews.com - November 26 at 9:24 AM
Alder BioPharmaceuticals® to Present at 29th Annual Piper Jaffray Healthcare Conference - NasdaqAlder BioPharmaceuticals® to Present at 29th Annual Piper Jaffray Healthcare Conference - Nasdaq
www.nasdaq.com - November 22 at 4:16 PM
Alder BioPharmaceuticals® to Present at 29th Annual Piper Jaffray Healthcare ConferenceAlder BioPharmaceuticals® to Present at 29th Annual Piper Jaffray Healthcare Conference
finance.yahoo.com - November 22 at 4:16 PM
First Week Of ALDR July 2018 Options TradingFirst Week Of ALDR July 2018 Options Trading
www.thestreet.com - November 21 at 4:16 PM
Top Growth Stocks in NovemberTop Growth Stocks in November
finance.yahoo.com - November 19 at 3:40 PM
Alder BioPharmaceuticals, Inc. (ALDR) Receives Consensus Recommendation of "Buy" from BrokeragesAlder BioPharmaceuticals, Inc. (ALDR) Receives Consensus Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - November 16 at 4:16 PM
Head to Head Review: Alder BioPharmaceuticals (ALDR) and Its RivalsHead to Head Review: Alder BioPharmaceuticals (ALDR) and Its Rivals
www.americanbankingnews.com - November 16 at 8:30 AM
Alder BioPharmaceuticals, Inc. (ALDR) Insider Mark James Litton Sells 16,519 SharesAlder BioPharmaceuticals, Inc. (ALDR) Insider Mark James Litton Sells 16,519 Shares
www.americanbankingnews.com - November 15 at 8:45 PM
Zacks: Analysts Expect Alder BioPharmaceuticals, Inc. (ALDR) Will Post Earnings of -$1.10 Per ShareZacks: Analysts Expect Alder BioPharmaceuticals, Inc. (ALDR) Will Post Earnings of -$1.10 Per Share
www.americanbankingnews.com - November 12 at 3:40 AM

SEC Filings

Alder Biopharmaceuticals (NASDAQ:ALDR) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Alder Biopharmaceuticals (NASDAQ:ALDR) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Alder Biopharmaceuticals (NASDAQ ALDR) Stock Chart for Wednesday, February, 21, 2018

Loading chart…

This page was last updated on 2/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.